沙美特罗氟替卡松联合噻托溴铵治疗慢性阻塞性肺疾病的临床效果(1)
[摘要]目的 观察并分析沙美特罗氟替卡松联合噻托溴铵治疗慢性阻塞性肺疾病(COPD)的临床效果。方法 选取2016年7月～2018年8月我院收治的100例COPD患者作为研究对象，根据随机数字表法分为对照组和观察组，每组各50例。对照组患者采用沙美特罗氟替卡松治疗，观察组患者采用沙美特罗氟替卡松联合噻托溴铵治疗，观察并比较两组患者的临床治疗效果以及肺功能水平。结果 两组患者治疗后的最大呼气流量比较，差异无统计学意义(P>0.05);观察组患者治疗后的第1秒用力呼气容积、第1秒用力呼气容积/预计值高于对照组，差异有统计学意义(P<0.05);观察组患者的临床治疗总有效率高于对照组，差异有统计学意义(P<0.05)。结论 采用沙美特罗氟替卡松联合噻托溴铵治疗COPD患者，可以有效改善患者的肺功能，提高患者的临床治疗效果。
[关键词]慢性阻塞性肺疾病;沙美特罗氟替卡松;噻托溴铵;临床效果
[中图分类号] R563 [文献标识码] A [文章编号] 1674-4721(2019)10(c)-0075-03
[Abstract] Objective To observe and analyze the clinical effect of Salmeterol Fluticasone combined with Tiotropium bromide in the treatment of chronic obstructive pulmonary disease (COPD). Methods One hundred patients with COPD treated in our hospital from July 2016 to August 2018 were selected as the study subjects. According to the random number table method， they were divided into the control group and the observation group， with 50 cases in each group. The control group was treated with Salmeterol Fluticasone. The observation group was treated with Salmeterol Fluticasone combined with Tiotropium. The clinical effects and lung function levels of the two groups were observed and compared. Results There was no significant difference in the maximum expiratory flow between the two groups after treatment (P>0.05). The first second forced respiratory volume and the first second forced respiratory volume/predicted value in the observation group were higher than those in the control group after treatment， and the differences were statistically significant (P<0.05). The total effective rate of clinical treatment in the observation group was higher than that in the control group， and the difference was statistically significant (P<0.05). Conclusion Salmeterol Fluticasone combined with Tiotropium in the treatment of patients with COPD can effectively improve the lung function of patients and improve the clinical treatment effect.
[Key words] Chronic obstructive pulmonary disease; Salmeterol Fluticasone; Tiotropium bromide; Clinical effect
慢性阻塞性肺疾病(COPD)是臨床中常见的一种慢性疾病，主要以长期反复的咳嗽、喘息以及胸闷等为临床症状表现[1]。目前对于COPD的治疗，主要的治疗原则为改善患者的肺部功能，并提高患者的通气质量。在临床中，多采用药物沙美特罗氟替卡松为处在稳定期的患者进行治疗;而药物噻托溴铵则可以帮助患者改善气流受限的情况，从而提高患者的肺功能。本研究选取我院收治的100例COPD患者作为研究对象，旨在探讨沙美特罗氟替卡松联合噻托溴铵治疗COPD的临床效果，现报道如下。
1资料与方法
1.1一般资料
选取2016年7月～2018年8月我院收治的100例COPD患者作为研究对象。纳入标准：①患者的年龄在45～75岁;②经临床检查均符合COPD的临床诊断标准[2];③患者及其家属均对本研究知情，且患者自愿同意参加本研究，已签署同意书。排除标准：①患有心脑血管疾病、肺部恶性肿瘤疾病、支气管疾病、神经系统疾病以及精神系统疾病的患者;②在短期内服用过糖皮质激素药物的患者;③对本研究采用的药物存在过敏反应的患者。本研究已经医院医学伦理委员会批准。, 百拇医药(王陈)
[关键词]慢性阻塞性肺疾病;沙美特罗氟替卡松;噻托溴铵;临床效果
[中图分类号] R563 [文献标识码] A [文章编号] 1674-4721(2019)10(c)-0075-03
[Abstract] Objective To observe and analyze the clinical effect of Salmeterol Fluticasone combined with Tiotropium bromide in the treatment of chronic obstructive pulmonary disease (COPD). Methods One hundred patients with COPD treated in our hospital from July 2016 to August 2018 were selected as the study subjects. According to the random number table method， they were divided into the control group and the observation group， with 50 cases in each group. The control group was treated with Salmeterol Fluticasone. The observation group was treated with Salmeterol Fluticasone combined with Tiotropium. The clinical effects and lung function levels of the two groups were observed and compared. Results There was no significant difference in the maximum expiratory flow between the two groups after treatment (P>0.05). The first second forced respiratory volume and the first second forced respiratory volume/predicted value in the observation group were higher than those in the control group after treatment， and the differences were statistically significant (P<0.05). The total effective rate of clinical treatment in the observation group was higher than that in the control group， and the difference was statistically significant (P<0.05). Conclusion Salmeterol Fluticasone combined with Tiotropium in the treatment of patients with COPD can effectively improve the lung function of patients and improve the clinical treatment effect.
[Key words] Chronic obstructive pulmonary disease; Salmeterol Fluticasone; Tiotropium bromide; Clinical effect
慢性阻塞性肺疾病(COPD)是臨床中常见的一种慢性疾病，主要以长期反复的咳嗽、喘息以及胸闷等为临床症状表现[1]。目前对于COPD的治疗，主要的治疗原则为改善患者的肺部功能，并提高患者的通气质量。在临床中，多采用药物沙美特罗氟替卡松为处在稳定期的患者进行治疗;而药物噻托溴铵则可以帮助患者改善气流受限的情况，从而提高患者的肺功能。本研究选取我院收治的100例COPD患者作为研究对象，旨在探讨沙美特罗氟替卡松联合噻托溴铵治疗COPD的临床效果，现报道如下。
1资料与方法
1.1一般资料
选取2016年7月～2018年8月我院收治的100例COPD患者作为研究对象。纳入标准：①患者的年龄在45～75岁;②经临床检查均符合COPD的临床诊断标准[2];③患者及其家属均对本研究知情，且患者自愿同意参加本研究，已签署同意书。排除标准：①患有心脑血管疾病、肺部恶性肿瘤疾病、支气管疾病、神经系统疾病以及精神系统疾病的患者;②在短期内服用过糖皮质激素药物的患者;③对本研究采用的药物存在过敏反应的患者。本研究已经医院医学伦理委员会批准。, 百拇医药(王陈)